FromMission Bio ([email protected])
Sent withSalesforce Marketing Cloud
Subject (67)[Blog Post] How single-cell multiomics rescued a "failed" AML trial
Preheader (150)Read the Blog Moving beyond the "average" in AML. In our latest blog, we dive into the re-analysis of the Phase II BLAST trial for Motixafortide. Init
Arial
Text Analysis
Body Words125
Subject Words10
Body Emojis1
Subject Emojis
Media Analysis
Text Links4
Image Links2
Total Links6
Images5
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px1223 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekWednesday
TimeMorning
![[Blog Post] How single-cell multiomics rescued a "failed" AML trial](https://images.spotmar.com/69c2a966a504d0a48270337e/orig.png)
![[Blog Post] How single-cell multiomics rescued a "failed" AML trial](/_next/image?url=https%3A%2F%2Fimages.spotmar.com%2F69c2a966a504d0a48270337e%2Forig.png&w=1080&q=75)